Combined treatment with TNF-α/gefitinib alleviates the resistance to gefitinib in PC-9 cells

Anti-Cancer Drugs

Volumn 20, Issue 9, 2009, Pages 832-837

  Ji, Yuan ^a   Ma, Sheng Lin ^c   Zhang, Yi Ping ^c   Tang, Juan Juan ^b   Wu, Yan Ming ^b   Lu, Yan Jun ^b  

^a FUDAN UNIVERSITY   (China)

^b TONGJI UNIVERSITY   (China)

^c ZHEJIANG CANCER HOSPITAL   (China)

Author keywords

Gefitinib; NF B p65; P Akt; P21 (waf1); Tumor necrosis factor

Indexed keywords

CYCLIN D1; CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE 4; CYCLIN E; GEFITINIB; PROTEIN KINASE B; PROTEIN P21; TRANSCRIPTION FACTOR RELA; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL CYCLE PROGRESSION; CELL DEATH; CONTROLLED STUDY; DRUG MECHANISM; DRUG POTENTIATION; DRUG RESISTANCE; HUMAN; HUMAN CELL; LUNG NON SMALL CELL CANCER; PRIORITY JOURNAL; WESTERN BLOTTING;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL CYCLE; CELL CYCLE PROTEINS; CELL DEATH; CELL LINE, TUMOR; CYCLIN-DEPENDENT KINASE INHIBITOR P21; DRUG RESISTANCE, NEOPLASM; HUMANS; LUNG NEOPLASMS; PROTO-ONCOGENE PROTEINS C-AKT; QUINAZOLINES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 70349113502     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/CAD.0b013e32832f4b64     Document Type: Article

References (30)

1. Fukuoka M, Yano S, Giaccone G, Tamura T, Nakagawa K, Douillard JY, et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer. J Clin Oncol 2003; 21:2237-2246.
2. Kris MG, Natale RB, Herbst RS, Lynch TJ Jr, Prager D, Belani CP, et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. J Am Med Assoc 2003; 290:2149-2158.
3. Frei E III, Spriggs D. Tumor necrosis factor, still a promising agent. J Clin Oncol 1989; 7:291-294.
4. Zhou QH, Hou M, Li L, Ren L, Qiu M, Yang YQ, et al. A multicenter randomized phase II trial of domestic product of nrh-TNF in the treatment of non-small cell lung cancer. Chin J Lung Cancer 2003; 6:42-45. (Pubitemid 36258487)
5. Chen Z, Liu ML, Huang WX. A clinical research on rnhTNF for 87 cases with advanced cancer. Chin J Clin Oncol 2003; 30:877-880.
6. Li EX, Li MZ, Nan KJ. Randomized-controlled study of recombinant mutant human tumor necrosis factor in advanced malignant tumor. Chin Oncol 2003; 13:353-355.
7. Lejeune FJ. High dose recombinant tumor necrosis factor (rTNFα) administered by isolation perfusion for advanced tumors of limbs: a model for biochemotherapy of cancer. Eur J Cancer 1995; 31:1009-1016.
8. Eggermont AMM, Schraffordt Koops H, Lienard D, Kroon BB, van Geel AN, Hoekstra HJ. Isolated limb perfusion with high-dose tumor necrosis factor-alpha in combination with interferon-gamma and melphalan for nonresectable extremity soft tissue sarcomas: a multicenter trial. J Clin Oncol 1996; 14:2653-2665. (Pubitemid 26329649)
9. Harper JW, Adami GR, Wei N, Keyomarsi K, Elledge SJ. The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclindependent kinases. Cell 1993; 75:805-816.
10. Hengst L, Gopfert U, Lashuel HA, Reed SI. Complete inhibition of Cdk/ cyclin by one molecule of p21 Cip1. Genes Dev 1998; 12:3882-3888.
11. Lu YJ, Tatsuka M, Takebe H, Yagi T. Involvement of cyclin-dependent kinases in doxorubicin-induced apoptosis in human tumor cells. Mol Carcinog 2000; 29:1-7.
12. Lu YJ, Yamagishi N, Miyakoshi J, Yagi T, Takebe H. Sites and types of UV-induced mutations leading to inactivation of the growth-arresting activity in p21(sdi1/cip1/waf1) cDNA. Carcinogenesis 1996; 17:2343-2345.
13. Lu YJ, Yamagishi N, Yagi T, Takebe H. Mutated p21WAF1/CIP1/SDI1 lacking CDK-inhibitory activity fails to prevent apoptosis in human colorectal carcinoma cells. Oncogene 1998; 16:705-712.
14. Engelman JA, Janne PA, Mermel C, Pearlberg J, Mukohara T, Fleet C, et al. ErbB-3 mediates phosphoinositide 3-kinase activity in gefitinib-sensitive non-small cell lung cancer cell lines. Proc Natl Acad Sci U S A 2005; 102:3788-3798.
15. Lynch TJ, Bell DW, Sordella R, Lynch TJ, Bell DW, Sordella R. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004; 350:2129-2139.
16. Paez JG, Jänne PA, Lee JC, Tracy S, Greulich H, Gabriel S, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004; 304:1497-1500.
17. Pao W, Miller V, Zakowski M, Doherty J, Politi K, Sarkaria I, et al. EGF receptor gene mutations are common in lung cancers from never smokers and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A 2004; 101:13306-13311.
18. Kosaka T, Yatabe Y, Endoh H, Yoshida K, Hida T, Tsuboi M, et al. Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications. Cancer Res 2004; 64:8919-8923.
19. Sun JZ, Nam S, Lee CS, Li BY, Coppola D, Hamilton AD, et al. CEP1612, a dipeptidyl proteasome inhibitor, induces p21WAF1 and p27KIP1 expression and apoptosis and inhibits the growth of the human lung adenocarcinoma A-549 in nude mice. Cancer Res 2001; 61:1280-1284.
20. van der Veen AH, Ten Hagen TLM, De Wilt JHY, van Ijken MJA, Eggermont AMM. An overview on the use of TNF-alpha: our experience with regional administration and developments towards new opportunities for systemic application. Anticancer Res 2000; 20:3467-3474.
21. Whiteside ST, Ernst MK, Lebail O, Laurent-Winter C, Rice N, Israel A. N-and C-terminal sequences control degradation of MAD3/I kappaB alpha in response to inducers of NF-kappa B activity. Mol Cell Biol 1995; 15:5339-5345.
22. Ma S, Tang J, Feng J, Xu Y, Yu X, Deng Q, Lu Y. Induction of p21 by p65 in p53 null cells treated with doxorubicin. Biochim Biophys Acta 2008; 1783:935-940.
23. Safrit JT, Bonavida B. Sensitivity of resistant human tumor cell lines to tumor necrosis factor and adriamycin used in combination: correlation between down-regulation of tumor necrosis factor-messenger RNA induction and overcoming resistance. Cancer Res 1992; 52:6630-6637.
24. Mizutani Y, Bonavida B. Overcoming cis-diamminedichloroplatinum (II) resistance of human ovarian tumor cells by combination treatment with cis-diamminedichloroplatinum (II) and tumor necrosis factor-alpha. Cancer 1992; 72:809-818.
25. Muzio M, Chinnaiyan AM, Kischkel FC, O'Rourke K, Shevchenko A, Ni J, et al. FLICE, a novel FADD-homologous ICE/CED-3-like protease, is recruited to the CD95 (Fas/APO-1) death-inducing signaling complex. Cell 1996; 85:817-827.
26. Cao W, Ma SL, Tang JJ, Shi JQ, Lu YJ. A combined treatment TNF-α/ doxorubicin alleviates the resistance of MCF-7/Adr cells to cytotoxic treatment. Biochim Biophys Acta 2006; 1763:182-187.
27. Ando K, Ohmon T, Inoue F, Kadofuku T, Hosaka T, Ishida H, et al. Enhancement of sensitivity to tumor necrosis factor α in non-small cell lung cancer cells with acquired resistance to gefitinib. Clin Cancer Res 2005; 11:8872-8879.
28. Cao W, Chi WH, Wang J, Tang JJ, Lu YJ. TNF-a promotes doxorubicininduced cell apoptosis and anti-cancer effect through downregulation of p21 in p53-deficient tumor cells. Biochem Biophys Res Commun 2005; 330:1034-1040.
29. Tang JJ, Shen C, Lu YJ. Requirement for pre-existing of p21 to prevent doxorubicin-induced apoptosis through inhibition of caspase-3 activation. Mol Cell Biochem 2006; 291:139-144.
30. Xiao GH, Beeser A, Chernoff J, Testal JR. p21-activated kinase links Rac/ Cdc42 signaling to merlin. J Biol Chem 2002; 277:883-886.